Literature DB >> 12381962

Acute renal failure following massive mannitol infusion.

Angel J Pérez-Pérez1, Beatriz Pazos, José Sobrado, Luis Gonzalez, Argimiro Gándara.   

Abstract

Mannitol overuse-induced acute renal failure (ARF) has rarely been described. We report four cases, all male, between the ages of 20 and 42 years, who developed acute renal failure (3 anuric, 1 nonoliguric) after receiving mannitol 1,172 +/- 439 g (mean +/- SD) during a time period of 58 +/- 28 h. The infusion rate was 0.25 +/- 0.02 g/kg/h. The onset of acute renal failure was detected 48 +/- 22 h after infusion. In 2 of the 3 cases in which urinary cytology was evaluated, the presence of vacuole-containing renal tubular cells was observed. All patients had hyponatremia (120 +/- 11 mEq/l), and hyperosmolality (osmolar gap 70 +/- 11 mosm/kg water). No other factors could be pointed to as causing acute renal failure. In the 3 anuric cases in which hemodialysis was performed, immediate recovery of diuresis was observed. Two patients recovered renal function on the fifth and sixth days, and 2 died due to endocranial hypertension - one of them while recovering - on the fourth and sixth days. In the present report, mannitol-induced ARF occurred at clustered doses of 0.25 mg/kg/h. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12381962     DOI: 10.1159/000065279

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  17 in total

1.  Pharmacotherapy Pearls for Emergency Neurological Life Support.

Authors:  Gretchen M Brophy; Theresa Human
Journal:  Neurocrit Care       Date:  2017-09       Impact factor: 3.210

2.  Vacuolar pathology in the median eminence of the hypothalamus after hyponatremia.

Authors:  Seymour Levine; Arthur Saltzman; Stephen D Ginsberg
Journal:  J Neuropathol Exp Neurol       Date:  2011-02       Impact factor: 3.685

3.  Mannitol improves cerebral oxygen content and postoperative recovery after prolonged retroperitoneal laparoscopy.

Authors:  Xiang Zhou; Ming-chun Wu; Yan-lin Wang; Xiao-yang Song; Na-jia Ling; Jun-zhe Yang; Dan Zhang; Bi-xi Li; Jun Tao
Journal:  Surg Endosc       Date:  2012-10-06       Impact factor: 4.584

4.  Comparison of hypertonic saline and mannitol on whole blood coagulation in vitro assessed by thromboelastometry.

Authors:  Teemu Luostarinen; Tomohisa Niiya; Alexey Schramko; Per Rosenberg; Tomi Niemi
Journal:  Neurocrit Care       Date:  2011-04       Impact factor: 3.210

5.  An embryo-fetal development toxicity study with dimethylaminoethyl ginkgolide B in rats and rabbits.

Authors:  Ronghua Li; Tingting Zhang; Mei Qin; Peng Yue; Ming Cai; Xuejun He; Hongqun Qiao
Journal:  Toxicol Res (Camb)       Date:  2018-08-28       Impact factor: 3.524

Review 6.  Hyperosmolar therapy for intracranial hypertension.

Authors:  Andrew Torre-Healy; Nicholas F Marko; Robert J Weil
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

7.  Use of High-Flow Continuous Renal Replacement Therapy with Citrate Anticoagulation to Control Intracranial Pressure by Maintaining Hypernatremia in a Patient with Acute Brain Injury and Renal Failure.

Authors:  Joshua E Medow; Shalin R Sanghvi; R Michael Hofmann
Journal:  Clin Med Res       Date:  2014-12-08

8.  Variable change in renal function by hypertonic saline.

Authors:  Jesse J Corry; Panayiotis Varelas; Tamer Abdelhak; Stacey Morris; Marlisa Hawley; Allison Hawkins; Michelle Jankowski
Journal:  World J Crit Care Med       Date:  2014-05-04

Review 9.  Use of Mannitol for Ischemia Reperfusion Injury in Kidney Transplant and Partial Nephrectomies-Review of Literature.

Authors:  Jose Alejandro Lugo-Baruqui; Rajinikanth Ayyathurai; Adavan Sriram; Kothai Divya Pragatheeshwar
Journal:  Curr Urol Rep       Date:  2019-01-26       Impact factor: 3.092

Review 10.  Emergency Neurological Life Support: Pharmacotherapy.

Authors:  Gretchen M Brophy; Theresa Human; Lori Shutter
Journal:  Neurocrit Care       Date:  2015-12       Impact factor: 3.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.